INVENTIVA - KBC Securities Company Note 24.01.2019 - No lack of ambition
Inventiva’s first major catalyst is imminent. In the coming days/weeks the company will reveal whether or not its flagship molecule Lanifibranor was successful in a phase IIb trial in systemic sclerosis. In this note we take a closer look at Lanifibranor’s target PPAR, other existing PPAR agonists and the space of SSc in general.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.